 SAN DIEGO, Oct. 12, 2021 GLOBE NEWSWIRE -- Otonomy, Inc. Nasdaq: OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the publication of its OTO-313 Phase 12 clinical trial results in Otology Neurotology, a leading peer-reviewed journal in otolaryngology. These are the first published results to demonstrate a reduction in tinnitus severity for a drug treatment compared to placebo using the Tinnitus Functional Index TFI, a clinically-validated instrument. 